Home LiteratureArticle Details
PMID: 8423216 Published · ppublish English Journal Article Research Support, U.S. Gov't, P.H.S.

High prevalence of mutations of the p53 gene in poorly differentiated human thyroid carcinomas.

The Journal of clinical investigation ·Vol. 91 ·No. 1 ·1993-01-00 ·Pages 179-84

Fagin JA, Matsuo K, Karmakar A, Chen DL, Tang SH, Koeffler HP

Abstract

The development and progression of thyroid tumors is signaled by phenotype-specific mutations of genes involved in growth control. Molecular events associated with undifferentiated thyroid cancer are not known. We examined normal, benign, and malignant thyroid tissue for structural abnormalities of the p53 tumor suppressor gene. Mutations were detected by single-strand conformation polymorphisms of PCR-amplified DNA, using primers bracketing the known hot spots on either exons 5, 6, 7, or 8. The prevalence of mutations was as follows: normal thyroid 0/6; follicular adenomas 0/31; papillary carcinomas 0/37; medullary carcinomas 0/2; follicular carcinomas 1/11; anaplastic carcinomas 5/6; thyroid carcinoma cell lines 3/4. Positive cases were confirmed by direct sequencing of the PCR products. All five anaplastic carcinoma tissues and the anaplastic carcinoma cell line ARO had G:C to A:T transitions leading to an Arg to His substitution at codon 273. In both tumors and cell lines, examples of heterozygous and homozygous p53 mutations were identified. The only thyroid carcinoma cell line in which p53 mutations were not detected in exons 5-8 had markedly decreased p53 mRNA levels, suggesting the presence of a structural abnormality of either p53 itself or of some factor controlling its expression. The presence of p53 mutations almost exclusively in poorly differentiated thyroid tumors and thyroid cancer cell lines suggests that inactivation of p53 may confer these neoplasms with aggressive properties, and further loss of differentiated function.

Related Genes
p53
MeSH Terms
Adenocarcinoma/genetics Adenoma/genetics Amino Acid Sequence Base Sequence Carcinoma/genetics Carcinoma, Papillary/genetics Codon Exons Genes, p53 Humans Molecular Sequence Data Mutation Oligodeoxyribonucleotides Polymerase Chain Reaction Polymorphism, Genetic Thyroid Gland/physiology Thyroid Neoplasms/genetics,pathology Tumor Cells, Cultured
Chemicals
Codon Oligodeoxyribonucleotides
Authors & Affiliations
6 authors, click to expand affiliations / ORCID
Fagin J A
Division of Endocrinology, UCLA School of Medicine 90048.
Matsuo K
Karmakar A
Chen D L
Tang S H
Koeffler H P
References (45)
45 references, click to expand
  1. Purification of biologically active globin messenger RNA by chromatography on oligothymidylic acid-cellulose.
    Proc Natl Acad Sci U S A. 1972 Jun;69(6):1408-12 PMID: 4504350
  2. p53 mutations: gains or losses?
    J Cell Biochem. 1991 Jan;45(1):22-9 PMID: 2005181
  3. T antigen is bound to a host protein in SV40-transformed cells.
    Nature. 1979 Mar 15;278(5701):261-3 PMID: 218111
  4. Characterization of a 54K dalton cellular SV40 tumor antigen present in SV40-transformed cells and uninfected embryonal carcinoma cells.
    Cell. 1979 May;17(1):43-52 PMID: 222475
  5. Carcinogenic epoxides of benzo[a]pyrene and cyclopenta[cd]pyrene induce base substitutions via specific transversions.
    Proc Natl Acad Sci U S A. 1982 Mar;79(6):1945-9 PMID: 7043469
  6. Isolation and characterization of full-length cDNA clones for human alpha-, beta-, and gamma-actin mRNAs: skeletal but not cytoplasmic actins have an amino-terminal cysteine that is subsequently removed.
    Mol Cell Biol. 1983 May;3(5):787-95 PMID: 6865942
  7. A technique for radiolabeling DNA restriction endonuclease fragments to high specific activity.
    Anal Biochem. 1983 Jul 1;132(1):6-13 PMID: 6312838
  8. Molecular cloning and in vitro expression of a cDNA clone for human cellular tumor antigen p53.
    Mol Cell Biol. 1985 Jul;5(7):1601-10 PMID: 3894933
  9. Characterization of the human p53 gene.
    Mol Cell Biol. 1986 May;6(5):1379-85 PMID: 2946935
  10. High frequency of ras oncogene activation in all stages of human thyroid tumorigenesis.
    Oncogene. 1989 Feb;4(2):159-64 PMID: 2648253
  11. A genetic model for colorectal tumorigenesis.
    Cell. 1990 Jun 1;61(5):759-67 PMID: 2188735
  12. Clonal composition of benign and malignant human thyroid tumors.
    J Clin Invest. 1990 Jul;86(1):120-5 PMID: 1973172
  13. Mutation of the p53 gene in human acute myelogenous leukemia.
    Blood. 1991 Apr 1;77(7):1500-7 PMID: 2009369
  14. Mutational hotspot in the p53 gene in human hepatocellular carcinomas.
    Nature. 1991 Apr 4;350(6317):427-8 PMID: 1849234
  15. Selective G to T mutations of p53 gene in hepatocellular carcinoma from southern Africa.
    Nature. 1991 Apr 4;350(6317):429-31 PMID: 1672732
  16. Maintenance of p53 alterations throughout breast cancer progression.
    Cancer Res. 1991 May 15;51(10):2605-10 PMID: 1850660
  17. Identification of p53 gene mutations in bladder cancers and urine samples.
    Science. 1991 May 3;252(5006):706-9 PMID: 2024123
  18. Overexpression and mutation of p53 in epithelial ovarian cancer.
    Cancer Res. 1991 Jun 1;51(11):2979-84 PMID: 2032235
  19. The p53 tumour suppressor gene.
    Nature. 1991 Jun 6;351(6326):453-6 PMID: 2046748
  20. p53 mutations in human lymphoid malignancies: association with Burkitt lymphoma and chronic lymphocytic leukemia.
    Proc Natl Acad Sci U S A. 1991 Jun 15;88(12):5413-7 PMID: 2052620
  21. Detection of aberrations of the p53 alleles and the gene transcript in human tumor cell lines by single-strand conformation polymorphism analysis.
    Cancer Res. 1991 Jul 1;51(13):3356-61 PMID: 2054775
  22. p53 mutations in human cancers.
    Science. 1991 Jul 5;253(5015):49-53 PMID: 1905840
  23. Thyroid adenocarcinomas secondary to tissue-specific expression of simian virus-40 large T-antigen in transgenic mice.
    Endocrinology. 1991 Sep;129(3):1391-401 PMID: 1714832
  24. Mutation of the p53 gene in a differentiated human thyroid carcinoma cell line, but not in primary thyroid tumours.
    Oncogene. 1991 Sep;6(9):1693-7 PMID: 1923534
  25. Cytogenetic and molecular genetic studies of follicular and papillary thyroid cancers.
    J Clin Invest. 1991 Nov;88(5):1596-604 PMID: 1939648
  26. Allelotype of human thyroid tumors: loss of chromosome 11q13 sequences in follicular neoplasms.
    Mol Endocrinol. 1991 Dec;5(12):1873-9 PMID: 1791835
  27. Oncogenic forms of p53 inhibit p53-regulated gene expression.
    Science. 1992 May 8;256(5058):827-30 PMID: 1589764
  28. Detection of polymorphisms of human DNA by gel electrophoresis as single-strand conformation polymorphisms.
    Proc Natl Acad Sci U S A. 1989 Apr;86(8):2766-70 PMID: 2565038
  29. Chromosome 17 deletions and p53 gene mutations in colorectal carcinomas.
    Science. 1989 Apr 14;244(4901):217-21 PMID: 2649981
  30. Characterization of a human follicular thyroid carcinoma cell line (UCLA RO 82 W-1).
    Virchows Arch B Cell Pathol Incl Mol Pathol. 1989;57(3):167-74 PMID: 2570483
  31. p53: a frequent target for genetic abnormalities in lung cancer.
    Science. 1989 Oct 27;246(4929):491-4 PMID: 2554494
  32. Mutations in the p53 gene occur in diverse human tumour types.
    Nature. 1989 Dec 7;342(6250):705-8 PMID: 2531845
  33. PTC is a novel rearranged form of the ret proto-oncogene and is frequently detected in vivo in human thyroid papillary carcinomas.
    Cell. 1990 Feb 23;60(4):557-63 PMID: 2406025
  34. Presence of mutations in all three ras genes in human thyroid tumors.
    Oncogene. 1990 Apr;5(4):565-70 PMID: 2183158
  35. Molecular basis of base substitution hotspots in Escherichia coli.
    Nature. 1978 Aug 24;274(5673):775-80 PMID: 355893
  36. Identification of intronic point mutations as an alternative mechanism for p53 inactivation in lung cancer.
    J Clin Invest. 1990 Jul;86(1):363-9 PMID: 2164047
  37. H-ras protooncogene mutations in human thyroid neoplasms.
    J Clin Endocrinol Metab. 1990 Jul;71(1):223-9 PMID: 2196280
  38. Transcriptional activation by wild-type but not transforming mutants of the p53 anti-oncogene.
    Science. 1990 Aug 31;249(4972):1049-51 PMID: 2144364
  39. 5-Methylcytosine as an endogenous mutagen in the human LDL receptor and p53 genes.
    Science. 1990 Sep 14;249(4974):1288-90 PMID: 1697983
  40. Mutations in the p53 gene are frequent in primary, resected non-small cell lung cancer. Lung Cancer Study Group.
    Oncogene. 1990 Oct;5(10):1603-10 PMID: 1979160
  41. p53 gene mutations occur in combination with 17p allelic deletions as late events in colorectal tumorigenesis.
    Cancer Res. 1990 Dec 1;50(23):7717-22 PMID: 2253215
  42. Frequent mutation of the p53 gene in human esophageal cancer.
    Proc Natl Acad Sci U S A. 1990 Dec;87(24):9958-61 PMID: 2263646
  43. Point mutations of ras oncogenes are an early event in thyroid tumorigenesis.
    Mol Endocrinol. 1990 Oct;4(10):1474-9 PMID: 2283998
  44. Mutant p53 DNA clones from human colon carcinomas cooperate with ras in transforming primary rat cells: a comparison of the "hot spot" mutant phenotypes.
    Cell Growth Differ. 1990 Dec;1(12):571-80 PMID: 2288874
  45. Activating mutations in p53 produce a common conformational effect. A monoclonal antibody specific for the mutant form.
    EMBO J. 1990 May;9(5):1595-602 PMID: 1691710
Article Info
Journal
The Journal of clinical investigation
Abbr.
J Clin Invest
ISSN
0021-9738
Published
1993-01-00
Pages
179-84
Language
English
Region
United States
NLM ID
7802877
PMCID
PMC330012
Subset
IM
Grants
NCI NIH HHS · R01 CA050706 · United States
NCI NIH HHS · CA-50706 · United States
NIDDK NIH HHS · DK-42792 · United States
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com